Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO)-Reference-Cited by-同舟云学术

Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO)

Published:2020-03-11 Issue:4 Volume:37 Page:1608-1619
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Adelman Daphne^ORCID,Truong Thanh Xuan-Mai,Feuilly Marion,Houchard Aude,Cella David

Funder

Ipsen

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12325-020-01255-8.pdf

Reference23 articles.

1. Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–33.

2. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–63.

3. Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol. 2010;16:2963–70.

4. Caron PJ, Bevan JS, Petersenn S, et al. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014;99:1282–90.

5. Khan MS, El-Khouly F, Davies P, Toumpanakis C, Caplin ME. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther. 2011;34:235–42.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors;Expert Opinion on Drug Safety;2024-06-10

2. Long-Acting Gel Formulations: Advancing Drug Delivery across Diverse Therapeutic Areas;Pharmaceuticals;2024-04-12

3. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story;Journal of Endocrinological Investigation;2023-08-15

4. Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours;Advances in Therapy;2023-08-12

5. An international simulated-use study to assess nurses’ preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3);Journal of Endocrinological Investigation;2023-08-08